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Abstract
Pathogenesis of preeclampsia involves immune dysfunction, placental  
implantation, abnormal angiogenesis, excessive inflammation, hypertension 
that may be affected by vitamin D. Human placenta expresses all the components 
for vitamin D signaling: Vitamin D receptor (VDR), retinoid X receptor (RXR), 
1-alpha- hydroxylase (CYP27B1) and 24- hydroxylase (CYP24A1). Vitamin D 
binding protein plays a role in binding and transportation of 25 hydroxyvita-
min D [25(OH)D] and 1,25(OH)2D3. Vitamin D is activated by 25-hydroxylase 
(CYP2R1) and 1-alpha -hydroxylase (CYP27B1) and is degraded by 24-hydroxylase 
(CYP24A1). Vitamin D supplementation is not recommended by WHO for preg-
nant women and allows recommended nutrient intake (RNI) of 200 IU (5 μg) per 
day. Further research requires serum 25(OH)D analysis and assessment of maternal 
and infant outcomes; pre-conceptional vitamin D status.
Keywords: Vitamin D, vitamin D receptor, cytochrome P450, pregnancy, 
preeclampsia, cord blood
1. Introduction
Pathogenesis of preeclampsia involves immune dysfunction, placental implanta-
tion, abnormal angiogenesis, excessive inflammation, hypertension that may be 
affected by vitamin D [1]. Preeclampsia complicates 2–8% of pregnancies globally 
and the incidence continues to increase worldwide. Preeclampsia (PE) is associated 
with significant maternal morbidity and mortality.
2. Pathogenesis of preeclampsia
Numerous pathophysiologic abnormalities have been suggested to explain the 
mechanisms of the origin of preeclampsia. Despite intensive research efforts, the 
etiology and pathogenesis of PE are not completely understood. The development 
of preeclampsia is influenced by genetic, immunologic, and environmental risk 
factors suggesting a multifactorial origin. Currently, there is no single reliable, 
cost-effective screening test for preeclampsia. A baseline laboratory evaluation is 
performed early in pregnancy in women who are at high risk for preeclampsia.
It is obvious that no single mechanism is responsible for this syndrome. The 
initiating abnormality is failed vascular remodeling of the vessels that supply the 
placental bed (stage 1). This was linked to the maternal syndrome of preeclamp-
sia (stage 2). Two key features in the pathogenesis of preeclampsia are shallow 




According to Barker’s theory (also, called fetal programming or fetal origins of 
disease), origin of some adulthood chronic diseases such as cardiovascular diseases, 
hypertension and diabetes have their origin in intrauterine life. This hypothesis sug-
gests that the intrauterine environment in which the fetus develops may be respon-
sible for complications in adult life. Changes occurring in intrauterine environment 
and that somehow could disrupt normal development of the fetus can trigger 
metabolic changes, which may result in the development of long-term disorders. 
Preeclampsia has implications for future pregnancies and future cardiovascular risk.
3. Vitamin D metabolism during pregnancy
Since fetus completely relies on the maternal stores for its growth and develop-
ment, vitamin D status during pregnancy has an important effect on this. During 
early pregnancy, 1,25(OH)2D increases and they continue to increase until delivery. 
This increase in 1,25(OH)2D is dependent on the available 25(OH)D levels and are 
independent of calcium metabolism (Figure 1).
The primary role of vitamin D in pregnancy is immunomodulatory in addition 
to its classical calcium regulatory function. According to Barker’s hypothesis, the 
developmental origins of adult disease lie mainly in prenatal factors such as nutri-
tional insults occurring during pregnancy and/or early infancy period [2].
Vitamin D metabolism during pregnancy and fetal development is different as 
compared with non-pregnant state, The conversion of vitamin D to 25(OH)D is 
unchanged during pregnancy. The conversion of 25(OH)D to 1,25(OH)2D during 
pregnancy is unique and unparalleled during life and at no other time during life 
25(OH)D is so closely linked with 1,25(OH)2D production.
During pregnancy, the rise in 1,25(OH)2D in the mother and fetus is dependent 
on substrate availability i.e., 25(OH)D, and this is largely independent of calcium 
Figure 1. 
Overview of vitamin D metabolism, its role  and mechanism of action.
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homeostasis. The 1,25(OH)2D serum concentrations double by 12th weeks of gesta-
tion and continue to rise two- to threefold from the non-pregnant baseline rising 
(to over 700 pmol·L−1) attaining levels that would be toxic due to hypercalcemia to 
the non-pregnant individual, but which are essential during pregnancy. Neither 
in the mother nor in the fetus during the pregnant state, this conversion seems to 
be controlled by classic calcium homeostatic mechanisms. Calcium homeostasis, 
however, is not linked with this increase in 1,25(OH)2D, because there is no increase 
in calcium demand by either the mother or fetus at 12 weeks of gestation. In 
contrast, the increased 1,25(OH)2D levels remain sustained during pregnancy and 
during lactation these levels are not sustained when the maternal calcium demands 
are high.
The mechanism of uncoupling of calcium metabolism from 1,25(OH)2D genera-
tion during pregnancy and not lactation is not clear. It could be due to the fact that 
1,25(OH)2D is an important immune modulator involved in maternal tolerance to 
the foreign fetus since pregnant women with preeclampsia have a clinical picture of 
inflammation and vasculitis, vitamin D deficiency has been implicated and vitamin 
D is a known modulator of inflammation [3].
Experimental animal studies have also strongly shown that vitamin D deficiency 
is a potential mechanism of placental dysfunction and respiratory maturation [4].
There is disruption of endothelial stability and an enhancement of “vascular 
leak” during preeclampsia and experimental animal models of preeclampsia have 
clearly demonstrated that endothelial instability leads to placental ischemia [5].
Vitamin D3,25(OH)D3 and 1,25(OH)2D3 stabilize endothelium and endothelium 
“leak” through non-genomic mechanisms and on equal molar basis, vitamin D3 has 
more potent action as compared to 25(OH)D3 or 1,25(OH)2D. Vitamin D3 is the most 
accessible form for cell membrane and it exists mainly bound to VDBP in circula-
tion and only miniscule amount of vitamin D3 exist in the free form. Vitamin D3 has 
a longer half-life following its endogenous synthesis (in skin) as compared to the 
exogenous vitamin D taken orally and the half-life of 25(OH)D is weeks. Vitamin D3 
when given at physiological doses of 4 000 IU·d−1 or greater circulates in the “free” 
form at significant levels to be available to membrane insertion and subsequent 
endothelial stabilization that is likely to have profound effects on several disease 
processes. Recent studies have implicated maternal vitamin D deficiency as a risk 
factor for abnormal fetal growth patterns, adverse birth outcomes, increased risk of 
preterm birth. and reproductive failure [6, 7].
1,25-dihydroxyvitamin D [1,25(OH)2D] is primary bioactive form, and it does 
not readily cross the placenta, umbilical cord concentrations of its precursor, 25(OH)
D, are similar to maternal concentrations. Placenta modulates circulating vitamin 
D metabolites in pregnant women and favors the uptake of DBP-bound 25(OH)D3 
through a specific receptor system (LRP2-CUBN) and has CYP27B1 activity.
Both maternal decidua and fetal trophoblast have detectable CYP27B1 activity 
and they express VDR. Placental production of 1,25(OH)2D has been documented 
to be essential for immunosuppressive effects required for immune tolerance of 
implantation. Vitamin D may have a more extensive role in placental function, 
including trophoblastic differentiation and extravillous trophoblast invasion of 
the decidua and myometrium and a fundamental role in the process of conception, 
implantation and development of the placenta itself. However, the precise role of 
vitamin D in the process of implantation remains unclear.
Studies have shown that 1,25(OH)2D regulates homeobox gene HOXA10 expres-
sion in human endometrial stromal cells which is important for the development of 
endometrial development and implantation. Animal studies have shown that female 
rats on a vitamin D-deficient diet had overall reduction of fertility and failure of 
implantation and administration of 1,25(OH)2D corrected this.
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In addition, vitamin D via its immunomodulatory actions may also influence 
implantation indirectly. Decidual synthesis of 1,25(OH)2D has the potential to 
influence uterine natural killer cells, dendritic cells, macrophages and T-cells 
throughout pregnancy, including inhibition of Th1 cytokines and promotion of 
Th2 cytokines, that have a significant role in the process of implantation [8].
Obesity is also a major contributing factor to vitamin D status in pregnant 
women that causes lowering of 25(OH)D levels in pregnant women with high body 
mass index (BMI).
4. Vitamin D signaling in pregnancy
Vitamin D signaling is important for normal placental function and fetal 
growth. Vitamin D maintains healthy cellular functions and redox and Ca2+ sig-
naling systems and increases expression of both Nrf2 and the anti-aging protein 
Klotho, a major regulator of Ca2+ and redox signaling. Declining vitamin D levels 
reduces the stability of this regulatory signaling network and may cause many 
of the major diseases linked to vitamin D deficiency which are associated with a 
dysregulation in both ROS and Ca2+ signaling [9].
Also, vitamin D signaling depends on availability and turnover of active 
vitamin D receptor (VDR) ligand 1,25-dihydroxycholecalciferol and efficiency of 
VDR transactivation. Net availability of active hormone depends on the delivery 
of substrate and the balance of activating and inactivating enzymes, mainly 
secosteroid metabolizing p450 enzymes (e.g., various hydroxylase enzymes: 25 
hydroxylase, 24 hydroxylase and 1- alpha hydroxylase). Out of these hydroxy-
lases, 1- alpha hydroxylase is expressed in kidney and released in systemic circula-
tion to serve as a critical activating enzyme in circulation. It is also synthesized 
in target tissues and activates local secosteroid. 1- alpha hydroxylase in kidney 
is upregulated by low calcium intake and parathyroid hormone inactivates both 
phosphatonins [10] as well as proinflammatory signal transduction downregulates 
its expression.
Transactivation of VDR depends on exact molecular structure, nuclear translo-
cation, and presence of heterodimer retinoid X-receptor (RXR) and other nuclear 
cofactors to regulate gene expression, however, membrane receptor for these effects 
is not yet identified.
Rickets is a syndrome of impaired vitamin D signaling due to vitamin D3 defi-
ciency and can be caused by inherited defects of the cascade, nutritional deficits, 
lack of sunlight exposure, malabsorption, and underlying diseases like chronic 
inflammation. Vitamin D signaling is complex and modulated at multiple levels.
1,25 (OH)2 D can diffuse freely across the plasma membrane and binds its high-
affinity nuclear receptor (VDR, vitamin D receptor) to mediate its effects tran-
scriptionally and post transcriptionally. In the transcriptional pathway, 1,25(OH)2D 
bind to VDR and forms a heterodimer complex (VDR- RXR complex) with retinoid 
X receptor (RXR). The VDR-RXR complex binds to vitamin D response element 
(VDRE) in the promoter region to regulate the target expression of vitamin D. Also, 
there is non-transcriptional pathway of vitamin D signaling having modulatory 
effects via binding of calcitriol- VDR complex with caveolae to stimulate signaling 
cascades namely, protein kinase C and mitogen-activated protein kinase. These 
signaling cascades regulate various cellular functions such as proliferation, differ-
entiation, invasion, and apoptosis. Altered VDR expressions have been associated 
with various cancers, however, role of VDR and vitamin D signaling in pregnancy is 
poorly understood.
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5. Vitamin D- induced genomic alterations during pregnancy
Vitamin D supplementation during pregnancy appears to affect genetic infor-
mation of several highly functional modules related to systemic inflammation and 
immune responses and implicates the emergence of a distinctive immune response 
in women destined to develop preeclampsia [11].
Both non-genomic and genomic actions of vitamin D can affect epigenetic 
regulation of fetal development, and dynamic changes occur in epigenetic markers 
namely, methylation, hydroxylation, post translational modifications (covalent 
modifications) various short and long RNAs that regulate the transcriptional 
gene activity during the acquirement of specific cellular functions. A subset of 
epigenetics are programmed during early pregnancy that are stably maintained into 
adulthood [12].
6. Role of vitamin D binding protein (VDBP) in PE
VDBP is plasma carrier protein that binds metabolites of vitamin D to be trans-
ported in the body. Vitamin D-binding protein [VDBP, group-specific component 
(GC) of serum (GC-globulin)] is encoded by the GC gene. VDBP is synthesized 
mainly in liver and synthesized in adipose tissue, kidneys, and gonads. VDBP is 
58 kDa glycosylated alpha-globulin composed of 458 amino acid residues in length 
and it folds into a triple-domain structure bound by disulphide bonds.
VDBP has immunomodulatory properties and is involved in chemotaxis of fatty 
acids and endotoxins. Immunological role for VDBP in pre-eclampsia in VDBP of 
placental origin has been documented as autoimmune target of autoantibodies in 
the sera of pre-eclamptic women compared with the sera of healthy non-pregnant 
women. Maternal obesity is associated with adverse health effects for both mother 
and newborn along with increased inflammation seems to be an important patho-
logical mechanism for detrimental effects of obesity during pregnancy. However, 
role of vitamin D in the process is still remains to be clarified.
VDBP-macrophage activating factor (DBP-MAF) is involved in bone metabo-
lism. VDBP has been shown to increase drastically during pregnancy as compared 
to non-pregnant women, reaching their peak in early third trimester and with the 
lowest level at approximately 36 weeks gestation. This increase is associated with 
increased total 25(OH)D and decreased free and bioavailable 25(OH)D to increase 
the capacity to store and metabolize more vitamin D to maintain sufficient concen-
tration of vitamin D throughout pregnancy and lactation to support their increased 
requirements.
The increase in VDBP during pregnancy could also occur in response to rising 
estrogen. VDBP has been reported to increase when oestrogens levels are increased 
in conditions such as high stress states, some ovarian tumors and hormone replace-
ment therapies.
Fetus obtains its supply of vitamin D via placenta which has also been shown 
to express VDBP. Placental cells express the components of vitamin D signaling 
including VDR and VDBP and can synthesize and respond to 1,25(OH)2D3 and 
24,25(OH)2D. The maternal vitamin D compounds may enter the placental cells 
by endocytosis of 25(OH)D-VDBP and/or by diffusion of the free hormone to be 
transformed into 1,25(OH)2D3 or 24,25(OH)2D, however, the exact mechanism is 
not known. Without VDBP maternally derived 25(OH)D may not enter placental 
cells and its transformation into the active form of vitamin D and its transport to 
the fetus for utilization would not be possible.
Preeclampsia
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SNPs of three genes involved in vitamin D metabolism including GC have been 
implicated in pre-eclampsia risk. GC-1 phenotype has been identified as a genetic 
marker for early detection for women at risk of pre-eclampsia. This has been shown 
that in South African (HIV endemic region) pregnant women complicated by 
pre-eclampsia that two SNPs of GC gene (rs4588 and rs7041) are more frequently 
present.
Status of VDBP and total 25(OH)D in preeclampsia is still not clear. Few studies 
have reported that different VDBP plasma concentrations in women who developed 
pre-eclampsia as compared to pregnant normotensive controls and no correlations 
have been noted between VDBP and total 25(OH)D. The increased oxidative stress 
in pregnancy may be responsible for the altered concentration of VDBP and vitamin 
D metabolism in placentae in preeclampsia. Moreover, proteinuria in preeclampsia 
have been shown to cause urinary loss of VDBP as compared to normotensive preg-
nancies possibly due to disruption of vitamin D metabolism and function through 
reduced VDBP.
Current evidence suggests that VDBP has been implicated in pregnancy, but its 
exact role is not yet fully understood. More focused studies are needed to address 
these limitations to disentangle the functions of VDBP and to clarify its role as a 
measure of vitamin D status and an important novel biomarker of pregnancy and 
reproductive outcomes.
7. Role of cytochrome P450 in PE
Two hepatic P450 enzymes catalyzing 25-hydroxylation of vitamin D3 (VD3) 
exist in mammalian liver namely, mitochondrial, and microsomal enzymes. 
Mitochondrial vitamin D3 25-hydroxylase is apparently identical with CYP27A.
VD3 is activated to 1α,25-dihydroxyvitamin D3 (1,25-D3) by cytochrome P450 
2R1 (CYP2R1)/CYP27A1 and CYP27B1 (1-alpha-hydroxylase) sequentially and 
deactivated by multiple enzymes including CYP3A4. 1,25-D3 can activate the tran-
scription of CYP3A genes. Activated vitamin D receptor (VDR) forms a heterodi-
mer with retinoid X receptor α (RXRα) to recruit co-activators and translocate this 
to the nucleus for its binding to specific vitamin D responsive elements (VDRE), 
and thus activates the gene transcription. This transactivation effect modulates 
the nutrient bioavailability and drug metabolism. Also, extrarenal expression of 
CYP27B1 (1-alpha-hydroxylase) generates 1,25(OH)2D in numerous target tissues 
including the placenta and brain. Vitamin D receptor (VDR) regulates cytochrome 
P450 3A (CYP3A) expression in human and VDR-response elements are found in 
the promoter region of CYP3A genes [13].
8. Vitamin D supplementation in pregnancy
Vitamin D dysregulation during pregnancy has been linked to adverse effects 
on placental function and pregnancy and there is requirement for adequate vitamin 
D status across gestation. Pregnant women are at high risk of vitamin D deficiency 
(VDD) and VDD during pregnancy is associated with increased risk of gestational 
diabetes and preeclampsia. Since preeclampsia can affect offspring health resulting 
in low birth weight, poor skeletal health, impaired brain development, autoimmune 
disease, obesity, and insulin resistance.
Randomized controlled trials investigating vitamin D supplementation during 
pregnancy have revealed that increased vitamin D supplementation decreased 
complications of pregnancy and C-section births and improve birth outcome data.
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Recent randomized controlled trials involving vitamin D supplementation 
in high-risk pregnancies have demonstrated decreased cesarean section rate and 
maternal hospitalization, decreased macrosomia and hospitalization in newborns 
of women with gestational diabetes. Favorable effects on insulin metabolism 
parameters, serum HDL cholesterol and total cholesterol concentrations in women 
with pre-eclampsia risk factors were also reported [14].
9. WHO recommendations
Vitamin D supplementation is not recommended for pregnant women to 
improve maternal and perinatal outcomes [15].
Remarks:
• These recommendation do not propose any alterations in the prevalent WHO 
recommendation regarding vitamin D supplementation during pregnancy as 
per WHO ANC guidelines.
• According to WHO guidelines on healthy eating, the pregnant women should 
receive adequate nutrition and consumption of healthy, balanced diet, according 
to WHO guidance on healthy eating during pregnancy.
• Since sunlight is one of important source of vitamin D and it is not known that 
how much duration of sunlight is required. This depends on various variables 
namely, amount of skin being exposed to sunlight, time of day, altitude and 
seasonal variations, pigmentation of skin (in darker skin, less vitamin D is 
synthesized by pigments are synthesized as compared to lighter pigments) and 
sunscreen use also decreases its production.
• In the cases of documented vitamin D deficiency or in pregnant women, 
vitamin D supplements may be given as per the guidelines of WHO
*This is an extract from the relevant guideline (https://www.who.int/
publications-detail-redirect/9789240008120).
10. Future research
The complexity of vitamin D metabolism and functions involved in placental 
development are still to be fully elucidated and they are likely to be a key compo-
nent of future studies of vitamin D in pregnancy. Further studies of vitamin D and 
adverse events in early pregnancy are required.
This needs to be clarified in future studies that how variations in vitamin D 
system in placenta and fetal trophoblast cells can affect implantation and regulate 
maintenance of a successful healthy pregnancy.
Role of vitamin D in maternal obesity is still not clear. Only a limited number of 
reports of vitamin D deficiency and miscarriage are available, and such studies need 
to be expanded by including more rigorous supplementation trials.
The mechanism of alteration of offspring epigenetic status by maternal VDD 
and the physiological impact of these epigenetic modifications remains uncertain. 
Future studies are needed to elucidate the mechanism and searching the windows 
for effective timely intervention via supplementation. Since VDD critically affects 
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neurobehavioral health, potentially via epigenetic mechanisms, exploration of 
mechanisms of non-genomic or genomic effects of vitamin D is required.
11. Conclusions
A proper understanding of causal mechanisms that lead to adverse health in 
offspring born to VDD mothers is required for early diagnoses and improving 
treatment during pregnancy so as to prevent later adverse DOHaD (developmental 
origins of adult disease) effects in at-risk offspring and mothers in future. Some 
genetic variants of VDBP have also been reported to be associated with these 
adverse outcomes. Further studies are required to explore more accurate VDBP 
assays and exploring ethnic variation and potential confounders are needed to 
clarify whether VDBP is associated with reproductive health and pregnancy 
outcomes, and the mechanisms underlying these relationships and possible role of 
vitamin D during pregnancy to prevent adverse fetal and maternal outcome.
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